Xcision Medical Systems, LLC

Xcision is a medical technology company developing a portfolio of advanced stereotactic radiotherapy solutions that are clinically superior to and more cost effective than existing technologies. The company’s technology has the potential to dramatically raise the quality of cancer treatments and improve the lives of patients and their loved ones. Founded in 2006, Xcision has developed the GammaPod, which is optimized for treating breast cancer, in collaboration with an NCI-designated Comprehensive Cancer Center. Xcision believes that GammaPod has the potential to revolutionize the management of breast cancer by eliminating surgery in many patients with early-stage disease. The system received FDA clearance in 2017 and CE mark in 2019.